Expression of mTOR pathway components and breast cancer metastasis to lung.

<p>(A) Kaplan-Meier lung metastasis-free survival (LMFS) and bone metastasis-free survival (BMFS) curves based on categorization of <i>TSC2</i> expression. The <i>P</i> values of the Cox proportional-hazards regression analysis are shown. (B) Tumor sample and gene expression clustering, and correlations of <i>TSC1/2</i> and genes from the lung metastasis signature, in the seminal breast cancer dataset [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0132546#pone.0132546.ref027" target="_blank">27</a>]. (C) GSEA results for Cox regression values of the mTOR pathway gene set and LMFS or BMFS. (D) GSEA results for Cox regression values of metabolic pathway gene sets and LMFS or BMFS. (E) Tumor sample and gene expression clustering, and correlations between <i>TSC1/2</i> and genes from lung metastasis signature, in the TCGA dataset [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0132546#pone.0132546.ref070" target="_blank">70</a>]. (F) GSEA results for the expression difference of the lung metastasis signature between MCF7 cells transduced with control or <i>TSC2</i>-target shRNAs. The left top panel shows the results for absolute expression differences, and the middle and bottom panels show the results for real differences of the up-regulated and down-regulated subsets of the signature, respectively. The right panels show the Western blot results for tuberin, pS6 and control loading, TUBA.